Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-based therapies

2 June 2014

Adaptimmune Limited, a leading biotechnology company developing TCR engineered T-cells to treat cancer, today announced that it has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialisation of its lead clinical cancer programme.

Please click on the link below to download the full Press Release:-

Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-based therapies

Bent Jakobsen speaking at AACR in San Diego

8 April 2014

Bent Jakobsen, CSO to Adaptimmune, is presenting at AACR in San Diego on Tuesday 8th April, 3.00pm – 5.00pm in the session entitled: “CIMT-AACR-CIMM Joint Session on Deciphering and modulating T-cell specificity in clinically effective antitumor responses”

AACR Conference

Adaptimmune announces full-time appointment of James Noble as Chief Executive Officer

26 March 2014

Adaptimmune Limited, the biotechnology company focused on the use of engineered T cells to treat cancer, today announced the full-time appointment of James Noble as Chief Executive Officer. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as CEO of sister company, Immunocore. He will remain on the Board of Immunocore as a non-executive director.

Please click on the link below to download the full Press Release:-

Adaptimmune announces full-time appointment of James Noble as Chief Executive Officer

 

Adaptimmune announces award of £2.1m from the Biomedical Catalyst Fund

25 March 2014

Adaptimmune has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

Please click on the link below to download the full Press Release:-

Adaptimmune announces award of £2.1m from the Biomedical Catalyst Fund

 

Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma

10 December 2013

Adaptimmune today announces the release of interim results from a Phase I/II clinical trial using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. The study Chair presented these updated results today at the annual meeting of the American Society of Hematology (ASH).

Please click on the link below to download the full Press Release:-

Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma

Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board

20 November 2013

Adaptimmune today announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect. Dr Knowles succeeds Nicholas Cross who has been Chairman of the company since foundation and will remain on the Board as Deputy Chairman.

Please click on the link below to download the full Press Release:-

Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board